Wednesday, October 14, 2026

Nikkei 225 Over 10% Up In The Last 21 Sessions

ViaNews Editorial Team

January 23, 2024

Nikkei 225 Over 10% Up In The Last 21 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 10.75% for the last 21 sessions. At 20:08 EST on Monday, 22 January, Nikkei 225 (N225) is $36,791.83.

About Nikkei 225's yearly highs and lows, it's 38.14% up from its 52-week low and 0.23% down from its 52-week high.

Volatility

Nikkei 225's last week, last month's, and last quarter's current intraday variation average was 0.65%, 0.58%, and 0.89%, respectively.

Nikkei 225's highest amplitude of average volatility was 0.86% (last week), 0.86% (last month), and 0.89% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikkei 225's is considered to be oversold (<=20).

News about

  • According to DailyForex on Monday, 22 January, "This catalyst could be the ongoing bull run in the stock market now that US indices like the S&P 500 and Nasdaq 100 have surged to a record high. "
  • According to FXStreet on Monday, 22 January, "However, the AUD could cheer the surge in the domestic share market, mirroring a rally in the US that propelled the S&P 500 and the Nasdaq to new records on Friday. "
  • According to Zacks on Monday, 22 January, "Between its January 2022 high and the October low, the S&P 500 had fallen 25% and was in the bear region. ", "Advancing issues outnumbered the declining ones on the S&P 500 by a 2.9-to-one ratio. "
  • According to DailyForex on Monday, 22 January, "At the same time, the main indices like the Dow Jones, Nasdaq 100, and S&P 500 indices continued rallying and moved to their all-time highs. "
  • According to Zacks on Monday, 22 January, "NRG Energy's current dividend yield is 2.88%, higher than the Zacks S&P 500 Composite's average of 1.36%."

More news about Nikkei 225 (N225).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com